Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity
- Conditions
- Healthy AgingLifestyle-related ConditionMetabolic Diseases
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: Nicotinamide Riboside (NR)
- Registration Number
- NCT06425042
- Lead Sponsor
- Finis Terrae University
- Brief Summary
The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 28
- Participants are able to provide signed and dated written informed consent prior to any study specific procedures
- Aged ≥ 60 and ≤ 80 years
- Body mass index (BMI) 25 - 35 kg/m2
- Stable dietary habits (no weight loss or gain > 5 kg in the past 3 months)
- No signs of active cardiovascular disease, liver or kidney malfunction
- Patients with congestive heart failure and and/or severe renal and or liver insufficiency
- Uncontrolled hypertension
- Any contra-indication for MRI scanning
- Alcohol consumption of > 3 servings per day for man and >2 servings per day for woman
- Smoking
- Unstable body weight (weight gain or loss > 5kg in the last 3 months)
- Engagement in structured exercise activities > 2 hours a week
- Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator which would possibly hamper our study results
- Use of food supplements containing NR or Resveratrol (similar working mechanisms)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PLA+EXTR Placebo This arm will ingest placebo orally and perform exercise training NR+EXTR Nicotinamide Riboside (NR) This arm will ingest NR orally and perform exercise training
- Primary Outcome Measures
Name Time Method Skeletal muscle mitochondrial respiratory capacity 12 weeks Skeletal muscle mitochondrial respiratory capacity will be measured in permeabilized fibres.
Skeletal muscle mitochondrial content 12 weeks Proteins content of oxidative phosphorylation system will be quantified from muscle biopsy
- Secondary Outcome Measures
Name Time Method Seating and standing transitions 12 weeks Time spent on performing seating and standing transitions will be measured upon the timed-up and go test
Body weight 12 weeks body weight will be measured in kilograms
Total muscle mass 12 weeks total muscle mass will be measured in kilograms and/or percentage
Total fat mass 12 weeks Total fat mass will be measured in kilograms and/or percentage
NAD+ levels 12 weeks NAD+ levels in circulation and in skeletal muscle
Maximal aerobic capacity 12 weeks Maximal aerobic capacity will be measure upon a progressive cycling test
Walking speed and distance 12 weeks Walking speed and distance will be measured via the 6-minutes walking test
Exercise efficiency 12 weeks Exercise efficiency will be measured upon a sub maximal cycling test and indirect calorimetry
Intrahepatic liver fat content 12 weeks Intrahepatic liver fat content will be measured by 1H-MRS
Fat-free mass 12 weeks Fat-free mass will be measured in kilograms and/or percentage
24h Blood pressure 12 weeks 24h Blood pressure will be measured with a continuous blood pressure holder device
Quantification of proteins that regulate oxidative metabolism 12 weeks Quantification of proteins content of oxidative phosphorylation system in muscle biopsies
Heart rate variability 12 weeks Heart rate variability will be measured with a continuos electrocardiogram monitor device
Resting energy expenditure 12 weeks Resting energy expenditure will be measured by indirect calorimetry
Trial Locations
- Locations (1)
Finis Terrae University
🇨🇱Santiago, Region Metropolitana, Chile